Open AccessSingle dose nonavalent HPV vaccine – need of the hour
Author(s) -
Manidip Pal,
Soma Bandyopadhyay
Publication year - 2020
Language(s) - English
Resource type - Journals
ISSN - 2091-0800
DOI - 10.3126/nje.v10i2.28962
Subject(s) - medicine , vaccination , herd immunity , girl , cervix , immunity , pediatrics , virology , immunology , immune system , cancer , psychology , developmental psychology
Human Papilloma Virus (HPV) vaccination of the preadolescent (9-14 years) females is the potential solution to eradicate carcinoma cervix. Nonavalent vaccine provides wider coverage than the quadrivalent vaccine. On long-term follow-up, even after single-dose HPV vaccination, the antibody titer remains good. Herd immunity can also be achieved by HPV vaccination. Hence, mass single-dose nonavalent HPV vaccination for sexually naive preadolescent girls can provide almost 100% protections and a cost-effective approach for the developing countries.